Long-term control of IOP is key to minimizing the ocular damage that eventually occurs in glaucoma patients. The effects of traditional anti-glaucoma eye drops are short-lived and therefore require diligent, long-term use. Even ALT, which is known to deliver effective results, starts to lose efficacy within several years. In contrast, SLT delivers effective IOP reduction that lasts far longer than any other treatment. In this video interview, SLT expert Lawrence F. Jindra shares his long-term results for SLT when used as a primary, secondary and replacement therapy. Watch the interview with Dr. Jindra to learn more.